Sign In
Buy TRVI
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2022 Results - Earnings Call Transcript
08:20am, Sunday, 14'th Aug 2022
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief
Trevi Therapeutics to Present at Upcoming August Conferences
07:30am, Tuesday, 09'th Aug 2022
NEW HAVEN, Conn. , Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine
Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022
05:41pm, Thursday, 04'th Aug 2022
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.
How to Find Trending Penny Stocks in 2022
02:00pm, Monday, 04'th Jul 2022
Tips for making a list of trending penny stocks in 2022 The post How to Find Trending Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Did Needham Lift Price Target For Trevi?
01:01pm, Thursday, 30'th Jun 2022
Yesterday Trevi Therapeutics Inc's (NASDAQ: TRVI) Phase 2b/3 trial (PRISM) evaluating Haduvio (nalbuphine ER) for prurigo nodularis (PN) successfully met the key primary and secondary endpoints.
Trending Penny Stocks to Add to Your Watchlist Right Now
01:00pm, Thursday, 30'th Jun 2022
Check these three penny stocks out for your watchlist right now The post Trending Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | P
Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical Data
10:51am, Wednesday, 29'th Jun 2022
Trevi Therapeutics (TRVI) stock is flying higher Wednesday following the release of positive trial data for its skin disease treatment! The post Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinic
3 Penny Stocks To Watch After GDP Report
10:03am, Wednesday, 29'th Jun 2022
Penny stocks to buy or avoid right now? You decide after seeing the latest updates from 3 companies.
Why Trevi Therapeutics Shares Trading Higher Today?
08:44am, Wednesday, 29'th Jun 2022
Trevi Therapeutics Inc (NASDAQ: TRVI) has announced positive results from its Phase 2b/3 PRISM trial of Haduvio in treating prurigo nodularis, a chronic disease characterized by severe pruritus and
Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention
07:30am, Tuesday, 07'th Jun 2022
NEW HAVEN, Conn. , June 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) f
Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q1 2022 Results - Earnings Call Transcript
02:40am, Saturday, 14'th May 2022
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Fin
Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon
02:49pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly
KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study
02:19pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.
TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down
03:02pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer-BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Ages 5-11
Pfizer Inc (
